Sponsor pipeline

Johnson & Johnson / Janssen clinical trial pipeline

Get alerts when Johnson & Johnson / Janssen's trials change

207 active trials 97 recruiting 79 Phase 3 29 disease areas 60 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 28 of 60 changes on 20 trials

2026-08-29
Primary completion pushed: 2027-12-29 → 2028-08-18
NCT07164443 A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line… · Phase 3
2026-08-29
Primary completion pushed: 2026-08-04 → 2027-04-01
NCT04929210 A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active… · Phase 4
2026-08-29
Primary completion pushed: 2028-12-29 → 2041-07-30
NCT05421663 A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma · Phase 1/2
2026-08-29
Primary completion pushed: 2027-01-28 → 2027-11-30
Completion pushed: 2027-03-01 → 2027-12-30
NCT07082920 A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer · Phase 1
2026-08-13
Enrollment reduced: 80 → 71 participants
Trial completed
NCT07324200 Objective Assessment of Intraocular Lens Tilt and Decentration
2026-09-01
Recruitment opened
Trial sites expanded: 0 → 3 locations
NCT07746713 A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer · Phase 1
2026-08-29
Trial completed
NCT06785012 A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive… · Phase 2
2026-08-29
Recruitment opened
NCT07654751 A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are… · Phase 4
2026-08-29
Enrollment closed, study ongoing
Final enrollment: 67 participants (planned 126)
NCT06116786 A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer · Phase 1
2026-08-21
Trial completed
NCT04936308 Guselkumab in Active Psoriatic Arthritis Participants With Inadequate… · Phase 3
2026-08-29
Primary completion pushed: 2026-10-31 → 2026-12-08
Completion pushed: 2026-10-31 → 2026-12-08
NCT05757869 A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation · Phase 3
2026-08-12
Trial completed
NCT05957276 Global Patient Registry of Inherited Retinal Diseases
2026-08-29
Primary completion pushed: 2026-07-31 → 2026-08-31
Completion pushed: 2026-07-31 → 2026-08-31
NCT07520747 A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With…
2026-08-21
Primary completion pushed: 2028-04 → 2028-07-11
Trial sites expanded: 12 → 18 locations
Completion moved earlier: 2030-04 → 2028-07-11
NCT06800313 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer · Phase 1/2
2026-09-02
Interventions modified
NCT07107230 A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors · Phase 1
2026-08-29
Enrollment increased: 15849 → 20167 participants
NCT00508547 Psoriasis Longitudinal Assessment and Registry
2026-08-29
Trial sites expanded: 30 → 39 locations
NCT07573176 A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major… · Phase 3
2026-08-29
Trial sites expanded: 55 → 142 locations
NCT07577843 A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease · Phase 3
2026-08-29
Trial sites expanded: 231 → 249 locations
NCT07438496 A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3
2026-08-29
Trial sites expanded: 63 → 170 locations
NCT07577856 A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative… · Phase 3

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-08-26 NCT07788521 Comparison of ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® Multifocal Not Yet Recruiting

Active trials by phase

Phase 1
48
Phase 1/2
12
Phase 2
32
Phase 2/3
6
Phase 3
73
Phase 4
6
Not charted: 30 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 207

NCT IDTitleConditionStatusUpdated
Phase 4
NCT05201781 A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel Multiple Myeloma Recruiting 2026-08-28
NCT07141004 A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants… Arthritis, Psoriatic Recruiting 2026-08-28
NCT07654751 A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are… Psoriasis Recruiting 2026-08-28
NCT07310095 A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's… Crohn Disease Recruiting 2026-08-27
NCT04929210 A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active… Arthritis, Psoriatic Active, Not Recruiting 2026-08-28
NCT07030517 A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and… Multiple Myeloma Active, Not Recruiting 2026-08-28
Phase 3
NCT04892173 JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC Carcinoma, Squamous Cell Recruiting 2026-08-28
NCT05552222 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and… Multiple Myeloma Recruiting 2026-08-28
NCT05912517 A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus… Hemolytic Disease of the Fetus and Newborn Recruiting 2026-08-28
NCT05923073 A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active… Crohn's Disease Recruiting 2026-08-28
NCT06319820 A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in… Non-Muscle Invasive Bladder Neoplasms Recruiting 2026-08-28
NCT06449651 A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune… Thrombocytopenia, Neonatal Alloimmune Recruiting 2026-08-28
NCT06533098 A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of… Thrombocytopenia, Neonatal Alloimmune Recruiting 2026-08-28
NCT06559306 Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants… Depressive Disorder, Major Recruiting 2026-08-28
NCT06662786 A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI… Colorectal Neoplasms Recruiting 2026-08-28
NCT06663332 A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants Crohns Disease Recruiting 2026-08-28
NCT06750094 A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in… Colorectal Neoplasms Recruiting 2026-08-28
NCT06807424 A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in… Arthritis, Psoriatic Recruiting 2026-08-28
NCT06852222 A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With… Leukemia, Myeloid, Acute Recruiting 2026-08-28
NCT06919965 A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants… Non-Muscle Invasive Bladder Neoplasms Recruiting 2026-08-28
NCT07164443 A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line… Metastatic Castration-resistant Prostatic Neoplasms Recruiting 2026-08-28
NCT07196748 A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to… Colitis, Ulcerative Recruiting 2026-08-28
NCT07217587 Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized… Myasthenia Gravis Recruiting 2026-08-28
NCT07225946 A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic… Prostatic Neoplasms, Castration-Resistant Recruiting 2026-08-28
NCT07227454 A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of… Depressive Disorder, Major Recruiting 2026-08-28
See all 207 active Johnson & Johnson / Janssen trials with filters →

Disease areas by active trials, top 10 of 29

Multiple Myeloma (31) · Crohn's Disease (21) · Non-Small Cell Lung Cancer (NSCLC) (17) · Leukemia (13) · Bladder Cancer (11) · Psoriasis (11) · Prostate Cancer (6) · Colorectal Cancer (4) · Depression (4) · Head & Neck Cancer (3)

Get alerts when Johnson & Johnson / Janssen's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free